APA

Hing Z. A., Fung H. Y. J., Ranganathan P., Mitchell S., El-Gamal D., Woyach J. A., Williams K., Goettl V. M., Smith J., Yu X., Meng X., Sun Q., Cagatay T., Lehman A. M., Lucas D. M., Baloglu E., Shacham S., Kauffman M. G., Byrd J. C., Chook Y. M., Garzon R. & Lapalombella R. (20170814). Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. : Leukemia.

Chicago

Hing Z A, Fung H Y J, Ranganathan P, Mitchell S, El-Gamal D, Woyach J A, Williams K, Goettl V M, Smith J, Yu X, Meng X, Sun Q, Cagatay T, Lehman A M, Lucas D M, Baloglu E, Shacham S, Kauffman M G, Byrd J C, Chook Y M, Garzon R and Lapalombella R. 20170814. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. : Leukemia.

Harvard

Hing Z. A., Fung H. Y. J., Ranganathan P., Mitchell S., El-Gamal D., Woyach J. A., Williams K., Goettl V. M., Smith J., Yu X., Meng X., Sun Q., Cagatay T., Lehman A. M., Lucas D. M., Baloglu E., Shacham S., Kauffman M. G., Byrd J. C., Chook Y. M., Garzon R. and Lapalombella R. (20170814). Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. : Leukemia.

MLA

Hing Z A, Fung H Y J, Ranganathan P, Mitchell S, El-Gamal D, Woyach J A, Williams K, Goettl V M, Smith J, Yu X, Meng X, Sun Q, Cagatay T, Lehman A M, Lucas D M, Baloglu E, Shacham S, Kauffman M G, Byrd J C, Chook Y M, Garzon R and Lapalombella R. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. : Leukemia. 20170814.